TOFA
| Code | Size | Price |
|---|
| AG-CR1-2905-M005 | 5 mg | £40.00 |
Quantity:
| AG-CR1-2905-M025 | 25 mg | £130.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Target Species: Universal
Shipping:
AMBIENT
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
RMI 14514; MDL 14514; 5-(Tetradecyloxy)-2-furoic acid; 5-(Tetradecyloxy)-2-furancarboxylic acid
Appearance:
White to off-white solid.
CAS:
54857-86-2
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.Protect from light.
InChi:
InChI=1S/C19H32O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-22-18-15-14-17(23-18)19(20)21/h14-15H,2-13,16H2,1H3,(H,20,21)
InChiKey:
CZRCFAOMWRAFIC-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 54857-86-2. Formula: C19H32O4. MW: 324.5. . Fatty acid synthase (FASN) inhibitor. Cell-permeable, potent, reversible and competitive inhibitor of acetyl-CoA carboxylase (ACC) consequently bocking the synthesis of malonyl-CoA. Useful agent for immunometabolism research. Anticancer agent. Induces apoptosis in a variety of tumor cell lines. Relatively non-cytotoxic to various cancer cell lines. TOFA-induced reduction in malonyl-CoA is reported to off-set the effect of C75 on food intake in fasted mice and on apoptosis in tumor cells. Hypolipidemic agent. Stimulates citrate accumulation in the cell, which leads to a suppression of glycolysis by citrate-induced inhibition of phosphofructokinase.
MDL:
MFCD01726059
Molecular Formula:
C19H32O4
Molecular Weight:
324.5
Package Type:
Vial
Product Description:
Fatty acid synthase (FASN) inhibitor. Cell permeable, potent, reversible and competitive inhibitor of acetyl-CoA carboxylase (ACC) consequently blocking the synthesis of malonyl-CoA. Useful agent for immunometabolism research. Anticancer agent. Induces apoptosis in a variety of tumor cell lines. Relatively non-cytotoxic to various cancer cell lines. TOFA-induced reduction in malonyl-CoA is reported to off-set the effect of C75 (AG-CR1-2904) on food intake in fasted mice and on apoptosis in tumor cells. Hypolipidemic agent. Stimulates citrate accumulation in the cell, which leads to a suppression of glycolysis by citrate-induced inhibition of phosphofructokinase.
Purity:
>98%
SMILES:
CCCCCCCCCCCCCCOC1=CC=C(C(O)=O)O1
Solubility Chemicals:
Soluble in DMSO (10mg/ml), DMF (5mg/ml) or ethanol (5mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids: R.A. Parker, et al.; J. Med. Chem. 20, 781 (1977) | Inhibition of fatty acid synthesis in isolated adipocytes by 5-(tetradecyloxy)-2-furoic acid: D.L. Halvorson & S.A. McCune; Lipids 19, 851 (1984) | Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines: E.S. Pizer, et al.; Cancer Res. 58, 4611 (1998) | Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors: T.M. Loftus, et al.; Science 288, 2379 (2000) | Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity: J.N. Thupari, et al.; BBRC 285, 217 (2001) | Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells: W. Zhou, et al.; Cancer Res. 63, 7330 (2003) | C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism: L.E. Landree, et al.; J. Biol. Chem. 279, 3817 (2004) | TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status: N.V. Guseva, et al.; Cancer Biol. Ther. 12, 80 (2011) | A guide to immunometabolism for immunologists: L.A. O'Neill, et al.; Nat. Rev. Immunol. 16, 553 (2016)
Related Products
| Product Name | Product Code | Supplier | Radicicol | AG-CN2-0021 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shikonin | AG-CN2-0487 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AICAR | AG-CR1-0061 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| C75 (FASN Inhibitor) | AG-CR1-2904 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2-Deoxy-D-glucose | AG-CR1-3681 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||